Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	68	92.43	141.2	125.57	98.71
Short-Term Investments	281.34	408.17	214	564.83	480.29
Cash & Cash Equivalents	349.33	500.59	355.2	690.41	579
Cash Growth	-30.22%	40.93%	-48.55%	19.24%	250.74%
Receivables	37.97	40.06	17.41	10.05	12.68
Inventory	14.45	14.45	19.26	14.06	9.07
Other Current Assets	8.44	7.04	10.88	12.4	11.94
Total Current Assets	410.19	562.15	402.75	726.91	612.69
Property, Plant & Equipment	120.32	164.21	172.94	139.04	60.36
Long-Term Investments	0	0	217.15	118.53	105.44
Goodwill and Intangibles	124.1	125.8	127.5	129.2	130.9
Other Long-Term Assets	6.52	4.46	3.01	2.74	2.92
Total Long-Term Assets	250.95	294.47	520.6	389.5	299.61
Total Assets	661.13	856.62	923.34	1,116	912.3
Accounts Payable	7.72	8.08	3.31	3.24	4.45
Deferred Revenue	93.42	122.71	179.21	236.94	280.33
Current Debt	9.38	9.23	5.06	3.53	0
Other Current Liabilities	-22.51	-30.24	-73.77	-138.51	-206.47
Total Current Liabilities	88.02	109.79	113.81	105.2	78.31
Long-Term Debt	220.05	224.13	106.69	104.33	36.61
Other Long-Term Liabilities	44.79	58.6	98.75	163.62	226.34
Total Long-Term Liabilities	264.84	282.73	205.44	267.95	262.95
Total Liabilities	352.86	392.52	319.24	373.15	341.26
Total Debt	229.43	233.36	111.74	107.86	36.61
Debt Growth	-1.68%	108.84%	3.60%	194.65%	-
Retained Earnings	-1,144.33	-919.08	-718.89	-511.61	-365.48
Comprehensive Income	0.22	-4.12	-1.14	0.89	0.67
Shareholders' Equity	308.4	464.17	603.99	743.27	571.04
Net Cash / Debt	119.9	267.23	243.46	582.55	542.4
Net Cash / Debt Growth	-55.13%	9.76%	-58.21%	7.40%	228.57%
Net Cash Per Share	0.83	1.88	1.73	4.44	7.84
Working Capital	322.17	452.36	288.94	621.72	534.38
Book Value Per Share	2.14	3.26	4.30	5.66	8.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).